Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2

Status

Completed 6Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 3Tumor-Agnostic 2CNS 2

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Brain Neoplasms 2Meningeal Carcinomatosis 1Glioblastoma 1

Interventions

Cyclophosphamide 1499Cisplatin 1434Paclitaxel 1339Radiotherapy 1310Carboplatin 1266Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 697Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × XL647 × Clear all
NCT00086528 2022-05-13

Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

Kadmon Corporation, LLC

Phase 1 Completed
41 enrolled
Tumor-Agnostic

Neoplasms

NCT00336765 2022-05-13

Study of XL647 Administered Orally Daily to Patients With Solid Tumors

Kadmon Corporation, LLC

Phase 1 Completed
31 enrolled
Tumor-Agnostic

Neoplasms

NCT00364780 2022-05-13

Study of XL647 in Subjects With Non-Small-Cell Lung Cancer

Kadmon Corporation, LLC

Phase 2 Completed
55 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00522145 2022-05-13

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

Kadmon Corporation, LLC

Phase 2 Completed
41 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02616393 2022-03-16

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Kadmon Corporation, LLC

Phase 2 Completed
36 enrolled 22 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT02844439 2021-09-22

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Kadmon Corporation, LLC

Phase 2 Completed
40 enrolled 25 charts
CNS

Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡